Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

episode

Urology Times Podcasts not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

FOOTBALL DAILY: Rovers aim to avoid having the Blues | Throwing the 'Kitching' sink | United's red flags 12 min · 18 Sep 2026 · OTB Football

NPR News: 09-18-2026 8AM EDT 4 min · 18 Sep 2026 · NPR News Now

The Price Tag Paradox_ Why Your Wallet Still Feels Empty (Part 2) 4 min · 18 Sep 2026 · Conspiracy Theories Exploring The Unseen

The Price Tag Paradox_ Why Your Wallet Still Feels Empty, Part 1 3 min · 18 Sep 2026 · Conspiracy Theories Exploring The Unseen

Body Scan Meditation (Repost) 14 min · 18 Sep 2026 · The Daily Meditation with Brother Richard

The Single Life_ Why People Over 60 Are Saying Enough (1) 3 min · 18 Sep 2026 · Conspiracy Theories Exploring The Unseen

Report any issue

Source

Recorded14 Mar 2022

Publisheraudioboom.com ↗

Handlerec:11143594

Show notes

In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Amy D. Dobberfuhl, MD, MS, about the presentation, “Feasibility and efficacy of transvaginal onabotulinumtoxinA chemodenervation of the trigone for the third line treatment of refractory overactive bladder,” which was given at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Winter Meeting. Dobberfuhl is a urologist at Stanford Hospitals and Clinics and an assistant professor of urology at the Stanford University School of Medicine in California.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in